Chemical Information | |
Antiviral agent ID | DrugRepV_0910 | |
Antiviral agent name | Tacrine Hydrochloride | |
IUPAC Name | 1,2,3,4-tetrahydroacridin-9-amine;hydrochloride | |
SMILES (canonical) | C1CCC2=NC3=CC=CC=C3C(=C2C1)N.Cl | |
Molecular Formula | C13H15ClN2 | |
Molecular Weight (g/mol) | 234.73 | |
InChl | InChI=1S/C13H14N2.ClH/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13;/h1,3,5,7H,2,4,6,8H2,(H2,14,15);1H | |
Common Name | Tacrine | |
Synonyms | 1,2,3,4-tetrahydro-9-acridinamine | 1,2,3,4-tetrahydro-9-aminoacridine | 1,2,3,4-tetrahydroacridin-9-amine | 5-amino-6,7,8,9-tetrahydroacridine | 9-amino-1,2,3,4-tetrahydroacridine | Tacrin | Tacrine | Tacrinum | Tetrahydroaminacrine | Tetrahydroaminoacridine | THA | |
Structural Information | |
|
|
Clinical Information | |
Category | Nervous System
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Non Infectious Disease
| |
Primary Indication (Disease) | Dementia
| |
Secondary Indication | Zika virus (ZIKV) NA MEX_I_7 | |
Secondary Indication (Approaches) | Experimental-HTS | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.4 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Pre infection (1 hour)
| |
Secondary Indication (Duration of drug delivery) | 24-26 hours
| |
Secondary Indication (Drug concentration) | 13.8 μM
| |
Secondary Indication (Cell based assay) | Fluorescence-based assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 57.39 % ] | |
Reference | Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Muñoz.A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection..Cell Host Microbe. 2016 Aug 10;20(2):259-70. doi: 10.1016/j.chom.2016.07.004. Epub 2016 Jul 28. PMID:27476412
| |
Comment | Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.
| |